🔗 Share this article

The recently developed medications for gonorrhoea in decades are being viewed as a "huge turning point" in the battle against superbug strains of the bacteria, according to health experts.

An International Public Health Issue

Gonorrhoea infections are increasing around the world, with estimates suggesting in excess of 82 million instances each year. Notably increased rates are seen in the African continent and countries within the World Health Organization's Western Pacific region, which encompasses Mongolia and China to New Zealand. In England, cases have reached a record high, while figures across Europe in 2023 were significantly elevated compared to figures for 2014.

“The authorization of new treatments for gonorrhoea is an important and timely advancement in the context of growing infection rates, increasing antimicrobial resistance and the very limited treatment choices at this time.”

Health officials are deeply concerned about the increase in antibiotic-resistant strains. The World Health Organization has classified it as a "critical concern". A tracking program showed that the effectiveness of primary antibiotics like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Two New Treatment Options Gain Approval

Zoliflodacin, alternatively called Nuzolvence, was authorized by the American regulatory agency in December for use against gonorrhoea. This STI can lead to significant complications, including the inability to conceive. Scientists hope that focused deployment of this new drug will help delay the emergence of superbugs.

Gepotidacin, originating from the drugmaker GSK, also received approval in concurrent days. This treatment, which is also used to treat urinary tract infections, was shown in trials to be effective against drug-resistant strains of the gonorrhoea bacteria.

A Unique Partnership

This new treatment was the result of a unique collaborative effort for antibiotic development. The non-profit organisation GARDP collaborated with the pharmaceutical company Innoviva to develop it.

“This milestone signifies a major breakthrough in the treatment of superbug gonorrhoea, which up to this point has been evolving faster than our drug pipeline.”

Research Study Results and Worldwide Availability

According to results detailed in a major medical journal, zoliflodacin cured more than 90% of genital gonorrhoea infections. This places it at an comparable level with the existing first-line therapy, which uses a dual-drug approach. The research involved over 900 patients from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its development partnership, GARDP has the ability to make available and distribute the drug in many developing nations.

Medical professionals directly involved have shared hope. The availability of a single-dose, oral treatment like this is seen as a "revolutionary step" for gonorrhoea control. This is viewed as vital to reduce the burden of the infection for patients and to halt the transmission of untreatable gonorrhoea worldwide.